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Background. Alzheimer’s, Parkinson’s and Creutzfeldt-Jakob disease are associated with inappropriate protein deposition and
ordered amyloid fibril assembly. Molecular chaperones, including aB-crystallin, play a role in the prevention of protein
deposition. Methodology/Principal Findings. A series of site-directed mutants of the human molecular chaperone, aB-
crystallin, were constructed which focused on the flexible C-terminal extension of the protein. We investigated the structural
role of this region as well as its role in the chaperone function of aB-crystallin under different types of protein aggregation, i.e.
disordered amorphous aggregation and ordered amyloid fibril assembly. It was found that mutation of lysine and glutamic
acid residues in the C-terminal extension of aB-crystallin resulted in proteins that had improved chaperone activity against
amyloid fibril forming target proteins compared to the wild-type protein. Conclusions/Significance. Together, our results
highlight the important role of the C-terminal region of aB-crystallin in regulating its secondary, tertiary and quaternary
structure and conferring thermostability to the protein. The capacity to genetically modify aB-crystallin for improved ability to
block amyloid fibril formation provides a platform for the future use of such engineered molecules in treatment of diseases
caused by amyloid fibril formation.
Citation: Treweek TM, Ecroyd H, Williams DM, Meehan S, Carver JA, et al (2007) Site-Directed Mutations in the C-Terminal Extension of Human aB-
Crystallin Affect Chaperone Function and Block Amyloid Fibril Formation. PLoS ONE 2(10): e1046. doi:10.1371/journal.pone.0001046
INTRODUCTION
The classic experiments of Anfinsen [1] on the folding of
ribonuclease in vitro revealed that all the information required for
folding of a polypeptide chain into its final native conformation is
contained within the polypeptide chain itself. This is indeed
evident with small proteins used for in vitro folding studies (e.g.
barnase, 110 residues) which are able to refold to their active
conformation in the absence of other proteins. In the case of large,
multi-domain proteins encoded by long sequences, however, only
a limited proportion achieve their native state unassisted [2]. Most
are prevented from reaching this state by incorrect intermolecular
interactions that occur when the protein is in a partially folded,
intermediate state, whereby hydrophobic regions on their surface
interact resulting in protein aggregation and precipitation. Thus,
protein folding and unfolding are exquisitely regulated in the cell
and involve molecular chaperone proteins that assist other proteins
in adopting their correct, native state. The small heat shock
proteins (sHsps) act in a chaperone manner by recognizing and
stabilizing the intermediate states of target proteins, thereby
preventing improper or incorrect folding that would otherwise
result in protein misfolding, aggregation, precipitation and possibly
disease [3,4,5,6]. aB-Crystallin is a sHsp that is capable of
interacting with a multitude of target proteins to prevent their
aggregation and precipitation [7]. However, unlike the classical
bacterial chaperonin GroEL, sHsps (including aB-crystallin) do
not directly participate in refolding of the denatured proteins,
except in the presence of another chaperone protein, e.g. Hsp70
[8]. sHsps act specifically with target proteins that are on their off-
folding pathway [9]. aB-Crystallin is primarily found in the eye
lens, where it associates with the closely related aA-crystallin,
which has 57% sequence homology with aB-crystallin and shares
the conserved ‘a-crystallin domain’ (reviewed in [10]), to form
large hetero-oligomeric species. However, it is also constitutively
expressed in many non-lenticular tissues, including the brain, lung
and cardiac and skeletal muscle where it forms complexes with
other sHsps [11]. As with other members of the sHsp family, the
expression of aB-crystallin is dramatically up-regulated in response
to stress and pathological conditions such as Alzheimer’s,
Parkinson’s and Creutzfeldt-Jakob diseases [4,12,13,14].
The sHsps form a structurally divergent protein family with
members present in archaea, bacteria and eukarya [10].
Monomeric molecular masses of the sHsps range between 12
and 40 kDa, however, most form large oligomeric assemblies of
150–800 kDa. All members are characterized by the presence of
a homologous sequence of 80–100 residues, referred to as the ‘a-
crystallin’ domain [15]. This domain is preceded by an N-terminal
domain, which is highly variable in size and sequence, and is
followed by a C-terminal extension. Whilst the C-terminal
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have the common characteristics of being polar and having
conformational flexibility similar to peptides of the same length
[16]. In previous studies, we have identified by
1H Nuclear
Magnetic Resonance (NMR) spectroscopy that Hsp25 and a-
crystallin have short, flexible and solvent exposed C-terminal
extensions, which protrude from the domain core of the molecule
[16,17,18].
The primary role of the flexible C-terminal extension of a-
crystallin is thought to be to act as a solubilizing agent for the
relatively hydrophobic protein and the sHsp-protein complex
formed by its chaperone action [19,20]. It may also play a role in
subunit interaction since the resolved crystal structures of plant
[21] and archaeal [22] sHsps indicate that their C-terminal
extensions wrap around the outer surface of the sHsp complex. A
similar role for the C-terminal extension of yeast Hsp26 has also
recently been reported [23]. During ageing, aB-crystallin under-
goes truncation of four C-terminal residues which correlates with
a reduction in the protective ability of the protein and an increase
in cataract formation [24]. Enzymatic truncation of the C-
terminus in vitro with calpain II or trypsin [25,26] or immobili-
zation of its flexibility through mutagenesis [27], results in
a reduction in its chaperone ability against amorphously
aggregating target proteins. Other site-directed modifications
within the C-terminal domain have also been shown to decrease
the chaperone activity of a-crystallin and other vertebrate sHsps
against amorphously aggregating target species [27,28,29,30].
Together these studies show that the C-terminal extension plays an
important role in the chaperone function of sHsps. However, to
date the role of individual amino acids in the C-terminal domain
of the protein has not been explored.
The interaction of sHsps with fibril-forming proteins has been
investigated (e.g. [31,32]) and it has been shown that a-crystallin
inhibits fibril formation by apolipoprotein C-II [33]. Moreover,
wild-type aB-crystallin is able to suppress fibril formation by b-
amyloid [34] and a-synuclein [35]. There is emerging evidence
that conformational changes in aB-crystallin give rise to a more
effective form of the chaperone. Phosphomimics of aB-crystallin
with altered structure [36] and a chimeric form of a-crystallin
(comprising aA- and aB-crystallin) have been shown to have
enhanced chaperone activity against amyloid fibril formation
compared to the wild-type protein [37].
In this study we have generated several mutants of aB-crystallin
in which the mutation sites are located in the C-terminal region of
the protein, in particular the flexible C-terminal extension. In
order to examine the role of specific C-terminal residues in
regulating the oligomeric structure and chaperone function of aB-
crystallin we have used a variety of biophysical techniques. As well,
the chaperone function of these mutants was compared with that
of the wild-type protein under different types of protein
aggregation, i.e. disordered amorphous aggregation and ordered
amyloid fibril assembly. The latter is of particular importance due
to its association with protein deposits found in diseases such as
Alzheimer’s, Parkinson’s and Creutzfeldt-Jakob disease.
METHODS
All reagents used were of analytical grade unless otherwise
specified. DEAE-Sephacel anion-exchange resin was obtained
from Sigma Chemical Co. (St. Louis, U. S. A.). Sephacryl S-
300HR size exclusion resin was obtained from GE Biosciences
(Uppsala, Sweden). Phenylmethylsulphonylfluoride (PMSF), poly-
ethylinimine (PEI), kanamycin sulphate, thioflavin T (ThT),
bovine k-casein and bovine pancreas insulin were obtained from
Sigma. Prior to use, the k-casein was reduced and carboxymethy-
lated as described previously [38]. Bovine bL-crystallin was
purified via size exclusion chromatography (SEC) using methods
described elsewhere [39,40] and subunit values involving bL-
crystallin were calculated based on the mass of the most abundant
component of bovine bL-crystallin, bB2, i.e. 26 kDa. The 18mer
coiled-coil a-helical peptide described previously [41], with
additional C-terminal tryptophan residue (ccb-Trp) was synthe-
sized by CS Bio Co. (San Carlos, CA, U. S. A.). Isopropanyl-b-D-
thiogalactopyranoside (IPTG), 5-bromo-4-chloro-3-indolyl-b-ga-
lactopyranoside (X-Gal), biotechnology grade agarose and Wi-
zardH SV DNA purification kits were all obtained from Promega
(Madison, U. S. A). Tris base, D-(+) glucose, glycine, lysozyme,
ampicillin sulphate and dithiothreitol (DTT) were purchased from
Astral Scientific (Carringbah, Australia). Tryptone, agar and yeast
extract were obtained from Oxoid (Heidelberg West, Australia).
Snakeskin dialysis tubing was obtained from Pierce (Rockford, U.
S. A). Restriction enzymes were obtained from Roche Biochem-
icals (Indianapolis, U. S. A), QuikChangeH Site-Directed Muta-
genesis kit was obtained from StratageneH (La Jolla, U. S. A.),
Big-DyeH Terminator ready reaction mix was obtained from
Applied Biosystems (Foster City, U. S. A). Uranyl acetate was
obtained from Agar Scientific (Essex, U. K.). The expression
vector pET24d(+) (Novagen, Madison, U. S. A.) containing the
gene for expression of human aB-crystallin was a gift from Prof.
W. de Jong (University of Nijmegen, Netherlands).
Site-directed mutagenesis of pET24d(+)-aB-crystallin
Site-directed mutagenesis was performed with the QuikChangeH
system (StratageneH, La Jolla, U. S. A.) on a Corbett Research
Cooled Palm 96 PCR machine (Corbett Research, Australia) as
per the manufacturer’s instructions with minor changes. All
primers were synthesized by Sigma Genosys (Castle Hill, Australia)
and 3% (v/v) Dimethylsulfoxide (DMSO) was added to muta-
genic reactions in which strong secondary interactions were
likely. Site-directed mutagenesis primers were as follows: I159A/
I161A, 59-GAGCGCACCGCTCCCGCCACCCGTGAAG-39;
R163STOP, 59-ACCATTCCCATCACCTGAGAAGAGAAG-
CCTGCT-39; E164A/E165A, 59-AATCCCATCACCCGTGCA-
GCGAAGCCTGCTGTCACC-39;K 1 7 4 A / K 1 7 5 A ,5 9-G T C A C -
CGCAGCCCCCGCGAAGTAGATGCCCTTTCTT-39;K 1 7 5 L ,
59-ACCGCAGCCCCCAAGTTATAGATGCCCTTTCTT-39.
Mutated codon/s are underlined. Site-directed mutagenesis was
confirmed using DNA sequence analysis with the following
primers: pET24d(+)-aB-crystallin forward 59-GTCAACCTGGA-
TGTGAAGCA-39 and pET24d(+)-aB-crystallin reverse 59-CAT-
TCACTGGTGGGGAAACT–39.
Plasmid DNA was routinely digested with Nco I and Hind III
confirm the presence of aB-crystallin gene insert prior to DNA
sequence analysis which was performed with Big-Dye Terminator
Ready Reaction Mix (PE Biosystems, U. S. A.) on an ABI-PRISM
377 DNA sequencer (Applied Biosystems, U. S. A).
Expression and purification of wild-type and mutant
aB-crystallins
Wild-type aB-crystallin and its C-terminal mutants were expressed
and purified as described previously [40] except that, following
ion-exchange chromatography, the I159A/I161A aB-crystallin
mutant was immediately dialyzed against 50 mM phosphate
buffer (pH 8.0) to avoid its aggregation and both I159A/I161A
and R163STOP aB-crystallin were also exhaustively dialyzed
against 50 mM sodium phosphate buffer (pH 7.4) following size-
exclusion chromatography in order to avoid the precipitation that
occurred when they were dialyzed against milliQ-water. Protein
aB-Crystallin Mutant Activity
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using a Cary 500 Scan UV-Vis-NIR spectrophotometer (Varian,
Melbourne, Australia) using the extinction coefficient for aB-
crystallin (E=19,000) [40] and molecular masses of the various
mutants from mass spectrometric analysis (Table 1).
Electrospray Ionisation Mass Spectrometry (ESI-MS)
and Nanoscale Electrospray Ionisation Mass
Spectrometry (NanoESI-MS)
Samples for ESI-MS were lyophilized after dialysis against milliQ-
water to remove any salts present (with the exception of the
I159A/I161A and R163STOP aB-crystallin mutants, which were
dialyzed against 100 mM ammonium acetate). These samples had
a final protein concentration of 1 mM. Nano-ESI-MS and ESI-MS
were performed on a Q-Tof
TM2 quadrupole orthogonal acceler-
ation time-of-flight mass spectrometer (Micromass U. K.,
Manchester, U. K.) with a Nanoflow-Z
TM interface. Resulting
spectra were processed with MassLynx
TM software.
Intrinsic tryptophan fluorescence
All fluorescence studies were performed on a Hitachi F-4500
fluorescence spectrophotometer with a 3 mL quartz fluorescence
cuvette. Wild-type and mutant aB-crystallins (10 mM) were
prepared in 50 mM sodium phosphate buffer, pH 7.2 and
tryptophan residues were excited at 295 nm and emission spectra
recorded from 300 to 400 nm. Slit widths for excitation and
emission were 5.0 and 2.5 nm, respectively.
Circular Dichroism (CD) spectroscopy
CD spectra were acquired with a Jasco J-810 spectropolarimeter
(Jasco, Victoria, Canada) with a Jasco circulating water bath at
25uC. Samples were prepared in pre-filtered 10 mM sodium
phosphate buffer, pH 7.5. aB-Crystallin samples for both near-UV
and far-UV spectra were approximately 1 mg/mL and were
filtered before analysis using 0.22 mm syringe filters. Near-UV
spectra were recorded from 240 to 320 nm in a 1 cm pathlength
cell and far-UV spectra recorded from 195 to 240 nm in a 0.01 cm
pathlength cell. In the near-UV and far-UV regions, spectra
represent the average of 16 and 32 scans, respectively. Mean
residue ellipticity was calculated from the protein samples
absorbance at 280 nm, residue number and the molecular weight
of each mutant and wild-type protein as determined by ESI-MS
(Table 1).
Size-exclusion HPLC (High Performance Liquid
Chromatography)
Aggregate sizes of wild-type and mutant proteins were analyzed by
size-exclusion chromatography on a PhenomenexH BioSep
TM
SEC S4000 column with an exclusion limit of 2,000,000 Daltons
(PhenomenexH, Torrance, U. S. A). A GBC/ICI HPLC system
was used (ICI, London, U. K.) with a mobile phase of 50 mM
sodium phosphate buffer, pH 7.2, an LC 1150 pump and LC 1440
systems organizer. Samples and standards were prepared at
10 mg/mL in 50 mM sodium phosphate, pH 7.2, with 0.02% (w/
v) NaN3, 2.5 mM EDTA and 0.1 M NaCl. A sample (10 mL) was
injected onto the column and eluted at 0.5 mL/min. The column
was calibrated under the same conditions using the following
standards; blue dextran (2.0 MDa), bovine thyroglobulin
(670 kDa), catalase (250 kDa), ovotransferrin (78 kDa), and bovine
serum albumin (BSA) (67 kDa). Approximate mass ranges of the
proteins were calculated from elution times at half-peak height.
Thermostability studies
Wild-type and mutant aB-crystallins were prepared in 50 mM
sodium phosphate buffer, pH 7.4. Protein (0.2 mg/mL) was
heated in a 1 mL quartz cuvette from 35uCt o8 5 uC in a Cary 500
Scan UV-Vis-NIR spectrophotometer equipped with a Cary
temperature controller. Thermal ramping of 1uC/min was
performed and protein precipitation in response to thermal stress
was monitored by measuring light scattering at 360 nm.
Chaperone activity assays
To test the relative activity of the chaperones, the aggregation and
precipitation of the target proteins under stress conditions was
monitored by either Thioflavin T (ThT) fluorescence or turbidity
assay (see below). Assays were conducted in 96-microwell plates by
incubating the target protein in the absence or presence of the
wild-type and mutant aB-crystallins following initial shaking for 5–
10 s. Light scattering at 340 nm was measured and recorded using
a Fluostar Optima plate reader (BMG Labtechnologies, Mel-
bourne, Australia). The relative change in light scattering at
340 nm for each sample is presented in the graphs. The change in
light scattering in the buffer control was negligible for each assay.
Bovine bL-crystallin (500 mg/mL) was incubated at 60uCi n
50 mM phosphate buffer, pH 7.2. Bovine pancreas insulin
(250 mg/mL) was incubated at 37uC in 50 mM phosphate buffer,
pH 7.2 and the aggregation and precipitation of the insulin B-
chain initiated by addition of dithiothreitol (DTT) to a final
concentration of 10 mM.
The formation of amyloid fibrils by target proteins was
monitored by an in situ ThT binding assay described previously
[42,43]. Briefly, reduced and carboxymethylated k-casein;
RCMk-casein (500 mg/mL) and ccb-Trp peptide (150 mg/mL)
were incubated at 37uC in 50 mM phosphate buffer, pH 7.4 with
10 mM ThT, in the absence or presence of the aB-crystallin
proteins. Microtitre plates were sealed to prevent evaporation and
the fluorescence levels measured with a Fluostar Optima plate
reader (BMG Labtechnologies) with a 440/490 nm excitation/
emission filter set. The change in ThT fluorescence measured for
each sample is presented. The change in ThT fluorescence in the
absence of the target protein was negligible for each assay. Also,
neither Bovine Serum Albumin (BSA) nor lysozyme had any effect
on the increase in ThT fluorescence when used in these assays in
place of aB-crystallin.
The relative chaperone ability of the aB-crystallin proteins was
assessed at the end of each assay by calculating the percentage
protection afforded by the chaperone using the formula:
Table 1. Molecular masses of recombinant proteins as
determined by ESI-MS.
......................................................................
Protein
Predicted Mass
(Da)
Actual Mass from
ESI-MS (Da)
Wild-type aB-crystallin 20159.0
1 20160.1
3
E164A/E165A aB-crystallin 20043.0
2 20043.0
I159A/I161A aB-crystallin 20074.9
2 20074.4
K174A/K175A aB-crystallin 20044.9
2 20044.8
K175L aB-crystallin 20144.0
2 20143.9
R163STOP aB-crystallin 18753.2
2 18752.0
1As given by SwissProt protein database, accession number P02511;
2Predicted masses were all calculated from average isotopic masses;
3Nanospray ESI-MS was used for this sample.
doi:10.1371/journal.pone.0001046.t001
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DI
where DI and DIchaperone represents the change in absorbance or
ThT fluorescence for the target protein in the absence and
presence of the chaperone respectively.
All experiments were replicated at least three times and the
statistical significance of any differences observed between group
means was determined by analysis of variance. Subsequent post-hoc
testing of differences between group means was accomplished using
the Tukey’s test with P,0.05 considered significantly different.
RESULTS
Molecular masses and purities of human recombinant aB-crystal-
lin proteins were assessed by ESI-MS (Table 1). The calculated
masses of the wild-type (aB-WT) and mutant aB-crystallins were in
excellent agreement with their predicted masses (max. 1.2 Da
difference). Peaks in the mass spectra arising from contaminating
proteins were minor (,10% or less). Intrinsic tryptophan
fluorescence of wild-type aB-crystallin produced a peak of
fluorescence at 338.2 nm that arises from Trp9 and Trp60
(Table 2). The K174A/K175A, K175L and I159A/I161A
mutants had red shifts in their wavelength maxima (lmax)
compared to the wild-type protein (338.8, 340.0 and 341.0 nm,
respectively). These data indicate that the tryptophan residues of
these mutant proteins are more exposed than in the wild-type
protein [36,44,45,46,47]. The E164A/E165A aB-crystallin mu-
tant displayed the most significant change in tryptophan polarity
with a blue shift in lmax to 336.0 nm implying a conformational
change in this mutant in which the tryptophan residues are buried
in the hydrophobic core to a greater extent than in wild-type
aB-crystallin. Similarly, the C-terminal truncation mutant
(R163STOP) displayed a lmax at a shorter wavelength
(337.0 nm) than wild-type aB-crystallin (Table 2).
The near-UV CD spectra of wild-type aB-crystallin exhibited
a distinct minima at ,267 nm and 292 nm and maxima at
around 258, 264 and ,273 nm (Fig. 1A) and was consistent with
CD spectra presented previously [40,48,49]. The K175L, E164A/
E165A and I159A/I161A mutants had very similar near-UV CD
spectra to wild-type aB-crystallin indicating that their tertiary
structures were not significantly altered by the mutation(s) (Fig. 1A).
However, the spectra of K174A/K175A and R163STOP aB-
crystallin showed a reduction in tertiary structure with a marked
decrease in the maximum ellipticity at 273 nm. As summarized by
Kelly [50] changes in this region of the spectrum are represen-
tative of the environment of the protein’s tryptophan residues.
Likewise, there is a reduction in the ellipticity of the bands
corresponding to the phenylalanine residues (,270 nm–250 nm).
Alteration in the tryptophan environment of R163STOP and
K174A/K175A is also reflected in the region of the spectrum from
280–292 nm. Taken together, these data are indicative of major
tertiary structural changes induced by these mutations.
The far-UV CD spectrum of wild-type aB-crystallin (Fig. 1B)i s
characteristic of a predominantly b-sheet protein, with a minimum
ellipticity at 213 nm. The majority of mutants had far-UV CD
spectraalmostidenticalto the wild-type protein with slight variations
in ellipticity only (Fig. 1B). The R163STOP mutant showed
significantly altered secondary structure compared to the wild-type
and other mutant aB-crystallins. The change in overall shape of the
spectrum, increased negative ellipticity (particularly in the region of
,225 nm) and appearance of the strong positive band at ,195 nm
are all indicative of increased a-helical content. This would be
consistentwiththe lossof theentire C-terminal extension, decreasing
the relative amount of b-sheet content compared to a-helix. In the
case of the K174A/K175A mutant, the loss of tertiary structure
observed in the near-UV region with concurrent retention of
secondarystructure as seeninthe far-UVregion of theCDspectrum
is indicative of a molten-globule like state similar to that observed for
a-crystallin in the presence of a denaturant [51].
Most of the aB-crystallins eluted from the size exclusion column
as relatively broad symmetrical peaks at early elution times
indicating they exist as polydisperse high molecular mass
oligomers (Fig. 1C). Wild-type aB-crystallin eluted in a single peak
corresponding to an average molecular mass of 740 kDa and mass
range of 420–980 kDa, consistent with previous studies [40,52].
All of the mutants form oligomers that are more polydisperse than
wild-type aB-crystallin (Fig. 1C). Both the E164A/E165A and
K175L mutants form oligomers that have a slightly reduced
average molecular mass (720 kDa and 670 kDa respectively)
compared to the wild-type protein. In contrast, the average
molecular mass of the K174A/K175A and I159A/I161A
oligomers is higher than wild-type aB-crystallin (780 kDa and
880 kDa respectively). The average molecular masses of oligomers
formed by the I159A/I161A mutant (up to 1.9 MDa) were found
to be significantly larger than the wild-type when tested using an
ANOVA with post-hoc analysis by Tukey’s test (P,0.019). Upon
visual inspection in can be seen that the ability of the R163STOP
mutant to form large and consistently sized aggregates was
profoundly impaired (Fig. 1C). Specifically, this mutant eluted in
the form of a high molecular mass species in the void of the
column (.2 MDa), at least two large molecular mass oligomers of
630 kDa and 310 kDa and a predominate peak corresponding to
a species of less than 100 kDa.
When its thermostability was assessed, wild-type aB-crystallin
began to precipitate from solution at 68uC and underwent a second
phase of precipitation at 78uC (Fig. 1D). The E164A/E165A aB-
crystallin mutant was much less thermostable than wild-type aB-
crystallin and the other mutants used in this study as evidenced by
its rapid, large-scale precipitation from solution at 60uC (Fig. 1D).
The change in light scattering due to precipitation for the E164A/
E165A mutant was more than 7-fold greater than for the other aB-
crystallin proteins. The K175L mutant showed very similar
thermostability to wild-type aB-crystallin with precipitation
occurring in two phases at 68uC and 78uC. The R163STOP and
I159A/I161A mutants were slightly less thermostable than wild-
type aB-crystallin with onset of precipitation observed at 63uC and
65uC respectively. The K174A/K175A aB-crystallin showed
enhanced thermostability compared to wild-type aB-crystallin,
with only minimal precipitation evident at 85uC (Fig. 1D).
The chaperone ability of the mutant aB-crystallin proteins was
compared to wild-type aB-crystallin under a variety of conditions
of induced target protein aggregation. The heat-induced amor-
Table 2. Maximum tryptophan emission wavelengths for wild-
type and mutant aB-crystallins.
......................................................................
Protein lmax (nm)
Wild-type aB-crystallin 338.2
E164A/E165A aB-crystallin 336.0
I159A/I161A aB-crystallin 341.0
K174A/K175A aB-crystallin 338.8
K175L aB-crystallin 340.0
R163STOP aB-crystallin 337.0
doi:10.1371/journal.pone.0001046.t002
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crystallin in the lens), incubated in the absence of the chaperone,
commenced after 20 min and the increase in light scattering due
to protein precipitation reached a maximum after 80 min (Fig. 2A).
Wild-type aB-crystallin was able to suppress the increase in light
scattering in a concentration dependent manner, such that, at
a 1.0:0.5 molar ratio of bL-crystallin: aB-crystallin, there was
complete inhibition of protein precipitation (data not shown). At
a 1.0:0.2 molar ratio of bL-crystallin:aB-crystallin the change in
light scattering after 90 min was reduced by 9062% (mean6
SEM) (Fig. 2A). When the mutant aB-crystallin proteins were used
at the same molar ratio (Fig. 2B), the E164A/E165A mutant was
a significantly worse chaperone than the wild-type protein
(p,0.01) and increased the amount of light scattering due to its
own precipitation from solution at this temperature (see Fig. 2A).
Whilst the I159A/I161A mutant delayed the onset of bL-
crystallin’s aggregation to 40 min, by the end of the assay the
amount of light scattering in the presence of this mutant was
similar to when bL-crystallin was incubated alone. The K174A/
K175A and K175L proteins were effective chaperones at this sub-
stoichiometric molar ratio to the target protein having activity
similar to the wild-type protein.
Reduction of insulin with DTT induced amorphous aggregation
of the B-chain after 10 min and the amount of light scattering due
to protein precipitation reached a plateau after 45 min (Fig. 2C).
Increasing the concentration of wild-type aB-crystallin prolonged
the lag phase of aggregation and decreased the change in light
scattering due to protein precipitation such that it was completely
suppressed at a 1.0:0.4 molar ratio of insulin: aB-crystallin (data
not shown). At a 1.0:0.14 molar ratio of insulin: aB-crystallin the
lag phase of aggregation was the same as when insulin was
incubated alone (10 min), but the rate of aggregation was
decreased such that the amount of protein precipitation after
90 min was reduced by 4063% (Fig. 2C). Comparing the
chaperone activity of the aB-crystallin mutants to the wild-type
protein at the same molar ratio showed that, whilst the E164A/
E165A delayed the onset of aggregation to 15 min, by the end of
the assay it was found to be a significantly worse chaperone
(p,0.05) (Fig. 2D). In contrast, the I159A/I161A mutant was
a significantly better chaperone (p,0.01), decreasing the amount
of light scattering due to protein precipitation by 6863% (Fig. 2D).
Both the K174A/K175A and K175L mutants had similar
chaperone ability as the wild-type protein in preventing the
DTT-induced aggregation of the insulin B-chain.
We also used the R163STOP protein in both these amorphous
aggregation assays to assess its relative chaperone ability compared
to the wild-type protein, but due to its destabilized structure only
a limited number of assays could be performed. The results of
Figure 1. Biophysical characterization of wild-type and mutant aB-crystallin proteins. A, Near- and B, Far-UV CD spectra of wild-type and mutant
aB-crystallin proteins. Spectra were acquired on a Jasco J-810 spectropolarimeter with 1 cm and 0.01 cm pathlength cells for the near- and far-UV
regions, respectively. Protein concentrations were ,1 mg/mL prepared in 10 mM sodium phosphate buffer, pH 7.4. C, Size-exclusion HPLC traces for
wild-type and mutant aB-crystallin proteins in 50 mM sodium phosphate buffer, pH 7.2. Samples (10 mL of a 10 mg/mL solution) were injected onto
the column and eluted at 0.5 mL/min. D, Thermostability profiles of aB-crystallin mutants. Protein samples were 0.2 mg/mL in 50 mM sodium
phosphate buffer, pH 7.4. Thermal ramping was 1uC/min and light scattering at 360 nm was monitored as an indicator of protein precipitation.
doi:10.1371/journal.pone.0001046.g001
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efficient chaperone than wild-type aB-crystallin against both the
heat-induced precipitation of bL-crystallin and DTT-induced
precipitation of the insulin B-chain (data not shown).
We employed two different models to examine the effect of
C-terminal mutation on the ability of aB-crystallin to prevent
amyloid fibril formation; reduced and carboxymethylated k-casein
(RCMk-CN), an unstructured or ‘‘natively unfolded’’ protein [53];
and ccb-Trp, a modified form of the ccb peptide that exists in
a helical coiled-coil configuration in its native state (Meehan,
Ecroyd and Carver, unpublished data). We employed these two
model systems since both form fibrils at physiological pH and
temperature [36]. Fibril formation by RCMk-CN, as monitored
by an increase in ThT fluorescence, showed a gradual increase
over the time course of the assay (Fig. 3A). The addition of aB-
crystallin to the sample slowed the rate of fibril formation such
that, at a 1.0:0.3 molar ratio of RCMk-CN: aB-crystallin, the
increase in ThT fluorescence was reduced by 2663% (Fig. 3B).
When the aB-crystallin mutants were used at the same
concentration, the E164A/E165A, K174A/K175A and K175L
mutants were more effective chaperones (p,0.01). The I159A/
I161A mutant was found to have a similar level of chaperone
ability against amyloid forming RCMk-CN as the wild-type
protein (Fig. 3B).
At 37uC, the increase in ThT fluorescence associated with fibril
formation by ccb-Trp was sigmoidal and included a short lag
phase of 30 min followed by an increase in fluorescence which
reached a plateau after 300 min (Fig. 3C). A 1.0:0.05 molar ratio
of ccb-Trp:aB-crystallin slowed the increase in ThT fluorescence
and therefore, by inference, amyloid fibril formation. Whilst the
overall trends in the relative chaperone ability of the wild-type and
mutant proteins were consistent with this assay, the absolute
percentage protection afforded by the chaperones was found to
vary between assays. The E164A/E165A aB-crystallin mutant was
more effective (p,0.01) at inhibiting the increase in ThT
fluorescence compared to the wild-type protein. The I159A/
I161A aB-crystallin mutant was found to be a very effective
chaperone for the first 600 min of the assay, but the increase in
ThT fluorescence increased significantly at this point such that, by
900 min, it afforded similar levels of protection against amyloid
fibril formation as wild-type aB-crystallin (Fig. 3D). The K175L
and K174A/K175A mutants had similar levels of chaperone
ability as the wild-type protein.
DISCUSSION
We have successfully produced and expressed a number of
mutants in the C-terminal region of aB-crystallin in order to
investigate the role of this region, and individual residues within it,
on the structure and chaperone function of this sHsp. In
particular, we have targeted key residues within the C-terminal
extension of the protein since it is thought to play an important
role in the chaperone action of other sHsps [19,20,29,54]. Overall,
our studies are consistent with previous work showing that a highly
flexible C-terminal extension in sHsps is important in the overall
structure of the chaperone protein. Significantly, we found that
certain residues in aB-crystallin play a key role in regulating its
chaperone activity towards particular types of protein aggregation
(i.e. ordered or disordered) and, therefore, these results may
Figure 2. The chaperone ability of wild-type and C-terminal mutants of aB-crystallin to prevent amorphous aggregation. A, Heat-induced
precipitation of bL-crystallin at 60uC and C, DTT-induced precipitation of insulin B-chain at 37uC, in the absence or presence of wild-type and mutant
aB-crystallins at a 1.0:0.2 molar ratio of bL-crystallin: aB-crystallin and a 1.0:0.14 molar ratio of insulin: aB-crystallin. The change in light scattering at
340 nm for each sample is shown. Each assay was repeated four times and the data shown are representative. B and D show the percentage
protection for each protein in the bL-crystallin and insulin B-chain aggregation assays respectively. The data in B and D represent the mean6standard
error of the mean (SEM) of the 4 different experiments, * denotes a significant (p,0.05) difference in the mean compared to wild-type aB-crystallin.
doi:10.1371/journal.pone.0001046.g002
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diseases associated with protein aggregation.
Our results have also shown that the C-terminal extension plays
a significant role in the oligomerization of aB-crystallin. Altered
oligomerization properties and increased polydispersity have been
shown to correlate with altered chaperone action of the a-
crystallins [52,55]. Each of the aB-crystallin mutants in this study
exhibited perturbed oligomeric association such that they had
broader molecular mass ranges than the wild-type protein. The
most dramatic changes were for the I159A/I161A and
R163STOP mutants. The I159A/I161A mutant eluted earlier
and formed aggregates that were much more polydisperse than the
wild-type protein, i.e. approximately 1.8 MDa to 490 kDa in mass
(with an average mass of 880 kDa). The I-X-I/V motif is well
conserved among sHsps, and in wheat Hsp 16.9 [21] and archael
Hsp16.5 [22], plays a critical role in oligomeric assembly. Indeed,
elimination of this motif from bacterial HspH leads to the
complete abrogation of the ability of the protein to oligomerise
and chaperone amorphously aggregating citrate synthase [56].
Our data support a role for this motif in regulating the
oligomerization of aB-crystallin (see Fig. 1). The altered fluores-
cence spectra of the various aB-crystallin mutants compared to the
wild-type protein are particularly interesting since the tryptophan
residues in aB-crystallin are located in the N-terminal domain
(Trp9 and Trp60). Our results indicate that in the case of K175L,
K174A/K175A and I159A/I161A aB-crystallin, the mutations
introduced resulted in conformational changes which led to the N-
terminal tryptophan residues becoming more exposed to solvent.
In contrast, the tryptophan fluorescence data of the E164A/
E165A mutant show that the conformational changes induced by
the loss of the two charged glutamic acid residues resulted in the
N-terminal region becoming buried to a greater extent. A similar
change was observed with the truncation of the C-terminal
extension in R163STOP aB-crystallin. As shown by size-exclusion
chromatography, the ability of this mutant to form regular
multimeric complexes was also profoundly impaired. The removal
of the highly flexible C-terminal extension led to the formation of
heterodisperse aB-crystallin multimers ranging from more than
100 subunits to less than 5 in size. These results are consistent with
studies of aA-crystallin showing that removal of residues from the
C-terminal extension of the protein alters its oligomeric distribu-
tion and decreases its subunit exchange rate [55,57]. Together, the
results show that the C-terminal extensions of both aA- and aB-
crystallin are not only important in maintaining the solubility of a-
crystallin and its complex with target proteins but also in
regulating the oligomerization of a-crystallin subunits into multi-
meric complexes. The C-terminal extension was one region
identified as being a subunit-subunit interaction site in human aB-
crystallin [58]. It has been proposed that the flexibility and polarity
of the C-terminal extension of Hsps plays an important role in
maintaining the spacing between adjacent complexes, which
would otherwise be prone to aggregation via hydrophobic
interactions [27]. Our results are consistent with this since
disruption of this spacing mechanism would be expected to give
rise to greater polydispersity, as is observed by size exclusion
HPLC (see Fig. 1C).
Figure 3. Inhibition of amyloid fibril formation by wild-type and C-terminal mutants of aB-crystallin. Thioflavin T (ThT) binding curves of A, RCMk-
casein and C ccb-Trp incubated at 37uC in 50 mM phosphate buffer, pH 7.4 in the absence or presence of wild-type and mutant aB-crystallins. The
chaperones were used at a 1.0:0.3 molar ratio of RCMk-casein:aB-crystallin and a 1.0:0.05 molar ratio of ccb-Trp:aB-crystallin respectively. The ThT
fluorescence was monitored by in situ assay for 15 h and the change in ThT fluorescence of each sample is shown. Each assay was repeated four
times and the data shown are representative. The data in B and D show the percentage protection for each protein in the RCMk-casein and ccb-Trp
assay systems respectively. These data represent the mean6SEM of 4 different experiments, * denotes a significant (p,0.05) difference in the mean
compared to wild-type aB-crystallin.
doi:10.1371/journal.pone.0001046.g003
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aB-crystallin also significantly altered the protein’s secondary and
tertiary structure (Fig. 1A and B). Together with the tryptophan
fluorescence data, these results indicate that the C-terminal
extension, although unstructured, plays a significant role in
stabilizing the structure of the entire protein. A similar effect was
observed in a C-terminally truncated mutant of Hsp25
(Hsp25DC18) where a loss of secondary and tertiary structure,
compared to the wild-type protein, was evidenced by far-UV CD
spectroscopy and 2D NMR spectroscopy [20]. The poor
chaperone activity of R163STOP aB-crystallin against amor-
phously aggregating target proteins is in keeping with previous
findings on deletion mutants of Hsps, i.e. Hsp25 [20], Hsp16.2
from C. elegans [54] and aA-crystallin [29].
Compared to the wild-type protein, the I159A/I161A aB-
crystallin mutant was a significantly worse chaperone against heat-
induced amorphously aggregating bL-crystallin, but was a signifi-
cantly better chaperone against the reduction-induced amorphous
aggregation of insulin (Fig. 2). These results are consistent with
previous studies on an I159/161G mutant of aB-crystallin which
exhibited enhanced chaperone ability under reduction stress [59].
In the present study, this mutant had similar chaperone ability
against amyloid fibril forming targets to the wild-type protein
highlighting the role of particular residues within the protein in
regulating chaperone action of aB-crystallin during different stress
conditions. For example, the increase in chaperone activity of
I159A/I161A compared to wild-type aB-crystallin in the re-
duction-induced amorphous aggregation assay conducted at
physiological temperatures may be due to the substitution of the
two bulky, hydrophobic isoleucine residues in the I-X-I motif with
more compact alanine residues. This in turn is likely to provide the
C-terminal extension with greater flexibility and hence, increase
the capacity of aB-crystallin to bind to some target proteins.
Another possibility is that the substitution of these residues gives
rise to a conformational change which further exposes putative
chaperone binding site(s) [21]. Interestingly, however, these
residues were not found to play a significant role in the chaperone
action of aB-crystallin against amyloid fibril forming target
proteins as there was no significant difference in the chaperone
action of this mutant and the wild-type protein. Together, these
data imply that the highly conserved I-X-I motif in sHsps regulates
exposure of the hydrophobic groove of the a-crystallin domain of
the protein, thereby controlling chaperone action with amor-
phously aggregating target proteins.
The increased thermostability of the K174A/K175A is consistent
with the results of Liao et al. who showed that removal of the C-
terminal lysine residue in porcine aB-crystallin led to a mutant with
a higher thermostability than the wild-type protein [60]. In contrast,
replacement of the ultimate lysine residue of the C-terminal
extension with a leucine residue did not affect the protein’s
thermostability to any significant extent [60]. Significantly, our
results show that the removal of these lysine residues does not
compromise the chaperone activity of the protein against amor-
phously aggregating target proteins and increased its chaperone
ability against aggregating RCMk-CN. Thus,these data suggest that
aB-crystallin does not require the two electropositive C-terminal
lysine residues in order to interact with aggregating target proteins.
The double glutamic acid aB-crystallin mutant (E164A/E165A)
showed greatly decreased thermostability and as a result was
ineffective as a chaperone in the heat stress assay. Whilst the
E164A/E165A mutant was able to delay the onset of aggregation
of reduced insulin, by the end of the assay it was found to be
a significantly worse chaperone than wild-type aB-crystallin. This
probably reflects the relative instability of the complex formed
between the insulin B-chain and E164A/E165A mutant protein.
Interestingly, E164A/E165A aB-crystallin was a significantly
better chaperone against the two amyloid fibril forming target
proteins used in this study. Thus, E164 and E165, which are
conserved between aA-and aB-crystallin, may play a role in
regulating chaperone interaction during different types of target
protein aggregation. The thermal instability of E164A/E165A aB-
crystallin may be attributable to the removal of hydrophilicity that
normally facilitates hydrophobic interactions within the protein,
since hydrophobic interactions increase with increasing tempera-
ture. By analogy with hyperthermophilic proteins, non-covalent
intermolecular interactions e.g. electrostatic and hydrogen bond-
ing [61,62] are facilitated by a high proportion of charged amino
acids that act to stabilise the protein at high temperatures, via the
formation of hydrogen bonds and salt bridges [62,63,64]. This
solubilising role is likely to be important both for the aB-crystallin
aggregate and the complex it forms with target proteins.
Furthermore, due to electrostatic repulsion, these two glutamic
acid residues may also function to separate protein subunits by
blocking hydrophobic interactions and thereby regulating aggre-
gate formation under heat stress.
Our results therefore highlight the important role of the C-
terminal region, and in particular the flexible C-terminal
extension, in the structure and chaperone function of aB-crystallin.
Of particular interest, specific amino acid residues within the C-
terminal region regulate its chaperone action against different
types of protein aggregation (i.e. ordered and disordered). The
mechanism by which aB-crystallin inhibits fibril growth is not
known but it may do so by interacting with and binding pre-
fibrillar aggregates in a soluble complex as it does with
amorphously aggregating proteins [36]. In the case of a-synuclein,
a component of Lewy bodies in Parkinson’s disease, aB-crystallin is
thought to interact with the fibril-forming species at an early stage
of its aggregation pathway to reduce the nucleation rate thereby
inhibiting fibril formation at the nucleation phase [35]. a-
Crystallin also interacts with early amyloidogenic precursors of
apolipoprotein C-II to inhibit nucleation [33]. Studies on the
Alzheimer’s disease protein, Ab peptide, showed that aB-crystallin
affected the elongation phase of fibril formation resulting in
shorter, non-regular fibrils [32]. More recent studies on the same
protein have shown that the chaperone preferentially binds to the
fibril nucleus preventing propagation of fibrillar species [37].
It has been suggested that aB-crystallin operates more effectively
as a chaperone against some target proteins than others as a result
of the differing affinities of the chaperone for the various
intermediately folded forms of its target [65,66]. These observa-
tions are also consistent with aB-crystallin possessing more than
one chaperone binding site, e.g. for amorphously aggregating
and/or amyloid forming proteins. The occurrence of numerous
binding sites on proteins which perform diverse functions has been
well documented. Hsp90 has been shown to possess two
independent binding sites with differential specificity [67] and
the E. coli chaperone SecB has multiple binding sites which are
both hydrophobic and hydrophilic in nature [68]. As discussed by
Haslbeck et al., the lack of conservation of residues amongst sHsps
makes it difficult to locate potential target protein binding sites
[69]. It is possible, therefore, that variable regions of sequence are
involved in binding which would help to explain why sHsps such
as aB-crystallin have such different target proteins affinities [69]. It
may also support the hypothesis that multiple target-protein
binding sites exist in the aB-crystallin sequence, which are affected
to a greater or lesser degree by conformational change.
Studies have shown that contacts between the I-X-I motif in the
C-terminal region and a hydrophobic grove in the aB-crystallin
aB-Crystallin Mutant Activity
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assembly in a plant sHsp [21]. It is possible; therefore, that irregular
oligomeric assembly of mutants such as E164A/E165A and I159A/
I161A aB-crystallin which form oligomers that are smaller and
larger, respectively, than wild-type aB-crystallin also alters target
protein binding at various sites. In the case of the E164A/E165A
mutant,forexample,removalofthepairofchargedresiduesinduced
a conformational change which decreased the protein’s stability
under heat stress, altered oligomerization and unfavorably affected
the binding of amorphously aggregating proteins. It is unclear at this
stage whether the reduced binding of such disordered aggregating
species occurs via obstruction or destabilization of such sites. In
doing so, however, it is feasible that the same conformational
changes may have exposed or stabilized another binding site on the
molecule for fibril forming proteins.
The observation that genetically modified aB-crystallin, in
comparison to the wild-type protein, demonstrates superior
chaperone ability to suppress the formation of amyloid fibrils is
a step in the potential development of treatments for diseases
associated with amyloid formation and deposition. Future studies
using in vivo models of amyloid fibril formation will elucidate the
potential of modified aB-crystallin (i.e. E164A/E165A) to serve as
therapeutic agents.
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